UCB and Novartis Hit a Roadblock: Parkinson’s Drug Trial Falls Short

A new experimental drug designed to treat Parkinson’s disease has failed to show any benefits in an important clinical trial. The drug, called minzasolmin, was being developed by UCB in partnership with Novartis. Despite hopes that it could slow the progression of the disease, results from the phase 2 trial, called ORCHESTRA, were disappointing. The Study and Its Results The trial involved 496 patients with early-stage Parkinson’s disease. Researchers were testing whether minzasolmin could improve symptoms using a standard disease rating scale over 18 months. Unfortunately, the drug did not meet the study’s main goals—or any of its secondary measures. On the bright side, the safety profile of the drug was consistent with previous findings, and no new risks were discovered. What Went Wrong? Minzasolmin was designed to target a protein called alpha-synuclein, which is believed to play a major role in Parkinson’s disease. In Parkinson’s patients, alpha-synuclein can misfold and form harmful clumps in the brain, leading to symptoms like tremors, stiffness, and mood changes. While many companies, including Biogen and Roche, have also tried to target alpha-synuclein, success has been elusive. Several drugs have failed in clinical trials over the years, though research is still ongoing. What’s Next for UCB? Despite this setback, UCB remains committed to finding better treatments for Parkinson’s disease. They are shifting their focus to other promising drugs, including: - UCB7583: This drug aims to stop the spread of harmful alpha-synuclein proteins between brain cells. - Glovadalen (UCB0022): An experimental drug that targets the dopamine D1 receptor in the brain to improve symptom control. Early results for glovadalen are expected in March 2025. A Message from UCB: UCB’s Chief Scientific Officer, Alistair Henry, thanked the patients, families, and doctors who participated in the study. “While this outcome is disappointing, we remain focused on delivering treatments that address the needs of Parkinson’s patients,” he said. The company is now analyzing other data from the ORCHESTRA study, including potential biomarker signals, and plans to publish its findings in a scientific journal soon.